We also identified SLC11A1 as a novel candidate prognostic marker for Th1 and Th2 responses, as demonstrated by the longer survival of the SLC11A1Low subgroup compared to that of the SLC11A1High subgroup, thereby indicating the role of Th cell status in GBM. This evidence concerns the gene SLC11A1 and glioblastoma.